Table 4. Comparison of therapies between C3dg/MAC positive versus negative patients at 6 and 12 months.
| C3dg | MAC | ||||||
|---|---|---|---|---|---|---|---|
| Positive for glomerular (n=48) | Negative for glomerular (n=30) | P | Positive for glomerular (n=48) | Negative for glomerular (n=30) | P | ||
| Therapy from 0–6 months, n (%) | |||||||
| Cyclophosphamide | 31 (64.6) | 10 (33.3) | 0.007 | 30 (62.5) | 11 (36.7) | 0.026 | |
| Mycophenolate mofetil | 10 (20.8) | 13 (43.3) | 0.034 | 8 (16.7) | 15 (50.0) | 0.002 | |
| Multitarget therapy | 4 (8.3) | 4 (13.3) | 0.479 | 5 (10.4) | 3 (10.0) | 1.0 | |
| Tacrolimus | 3 (6.3) | 4 (13.3) | 0.511 | 5 (10.4) | 1 (3.3) | 0.481 | |
| Hydroxychloroquine at 6 months | 48 (100.0) | 30 (100.0) | 48 (100.0) | 30 (100.0) | |||
| Noncompliance at 6 months | 43 (89.6) | 30 (100.0) | 0.150 | 42 (87.5) | 30 (100.0) | 0.077 | |
| Response to therapy at 6 monthsa, n (%) | |||||||
| No | 0 | 0 | 0 | 0 | |||
| Yes | 48 (100.0) | 30 (100.0) | 48 (100.0) | 30 (100.0) | |||
| Therapy from 6–12 months, n (%) | |||||||
| Cyclophosphamide | 0 | 0 | 0 | 0 | |||
| Mycophenolate mofetil | 45 (93.8) | 23 (76.7) | 0.028 | 42 (87.5) | 28 (93.3) | 0.658 | |
| Multitarget therapy | 2 (4.2) | 3 (10.0) | 0.584 | 3 (6.3) | 1 (3.3) | 0.968 | |
| Tacrolimus | 3 (6.3) | 4 (13.3) | 0.511 | 5 (10.4) | 1 (3.3) | 0.481 | |
| Noncompliance at 12 months | 32 (66.7) | 28 (93.3) | 0.015 | 35 (72.9) | 29 (96.7) | 0.018 | |
| Response to therapy at 12 monthsb, n (%) | |||||||
| No | 11 (22.9) | 1 (3.3) | 0.017 | 11 (22.9) | 0 | <0.001 | |
| Yes | 37 (77.1) | 29 (96.7) | 0.044 | 37 (77.1) | 30 (100.0) | <0.001 | |
a, response to therapy at 6 months is defined as a reduction in proteinuria of at least 50%; b, response to therapy at 12 months is defined as complete response. MAC, membrane attack complex.